| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Heparin Xa, Low Molecular Weight
Test CodeLMWH
Alias/See Also
LMWH, XA, Heparin, Heparin XA
CPT Codes
85520
Preferred Specimen
Citrate (BLU)
Instructions
Collect whole blood in 3.2% buffered sodium citrate (9:1 blood to sodium citrate). Venipuncture must be atraumatic.
Specimen Stability
- Centrifuge at the appropriate time and RPM's for the plasma to have a platelet count less than 10,000. Plasma platelet count should be less than 10,000.
- Test within four hours of collection. If testing is to be delayed more than four hours, immediately separate plasma into a clean, polystyrene tube, cap and store below -20°C up to two weeks or -70°C up to 6 months.
- In patients with hematocrit values greater than 55%, the citrate concentration must be adjusted so that a proper plasma/anticoagulant volume is maintained.
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Reject hemolyzed, clotted, overfilled tubes or short draw (<90%) samples.
Setup Schedule
24x7
Reference Range
VTE Prophylaxis reference range: 0.1 - 0.3 IU/mL
Treatment of VTE: Optimal target ranges for LMWH depend on the schedule of treatment (eg. once or twice daily) and the preparation used. Recommended target (peak) ranges measured four hours after dosing (with dose reduction considered if the anti-factor Xa activity four hours after subcutaneous injection is excessive) are:
Enoxaparin or nadroparin, dosed twice daily: 0.6 to 1.0 IU/mL
Enoxaparin, dosed once daily: >1.0 IU/mL
Nadroparin, dosed once daily: 1.3 IU/mL
Tinzaparin, dosed once daily: 0.85 IU/mL
Dalteparin, dosed once daily: 1.05 IU/mL
This assay is not intended for measure of Rivaroxaban (Xarelto), Apixaban (eliquis), Fondaparinux (Arixtra), or Argatroban.
Treatment of VTE: Optimal target ranges for LMWH depend on the schedule of treatment (eg. once or twice daily) and the preparation used. Recommended target (peak) ranges measured four hours after dosing (with dose reduction considered if the anti-factor Xa activity four hours after subcutaneous injection is excessive) are:
Enoxaparin or nadroparin, dosed twice daily: 0.6 to 1.0 IU/mL
Enoxaparin, dosed once daily: >1.0 IU/mL
Nadroparin, dosed once daily: 1.3 IU/mL
Tinzaparin, dosed once daily: 0.85 IU/mL
Dalteparin, dosed once daily: 1.05 IU/mL
This assay is not intended for measure of Rivaroxaban (Xarelto), Apixaban (eliquis), Fondaparinux (Arixtra), or Argatroban.
Performing Laboratory
CRMC Laboratory
